Background: Anticoagulants and antiplatelet drugs are risk factors for gross hematuria (GH). Moreover, co-medication and drug-drug interactions (DDIs) may influence GH and its clinical course.
Objective: To investigate the relationship between GH and administration of oral anticoagulants and antiplatelet drugs.
Design, Setting, And Participants: Hospitalized patients with GH in an academic tertiary reference center were included. The use of individual compounds and DDIs were recorded and correlated to relevant clinical outcome factors.
Outcome Measurements And Statistical Analysis: The association between GH, DDIs, and clinical outcome parameters was analyzed using χ and Kruskal-Wallis tests. DDIs were systematically evaluated using a previously published calculator.
Results And Limitations: A total of 189 patients with GH were eligible for the study. Of these, 76.2% took anticoagulants or antiplatelet drugs. The mean hospitalization duration was 4.7 d. The mean bladder irrigation duration was 3.1 d and the mean volume of irrigation fluid used was 22.8 l. Overall, 30.7% of patients had a pre-existing genitourinary malignancy. DDIs were observed in 31.9% of cases. The irrigation duration (p = 0.01) and volume of irrigation fluid (p = 0.05) were significantly associated with the use of anticoagulants or antiplatelet drugs. Specific DDI patterns were not predictive of clinical outcome.
Conclusions: Medication with anticoagulants or antiplatelet drugs has a significant impact on GH and its clinical course. DDIs are a relevant issue and may lead to adverse clinical events or greater drug toxicity. Critical evaluation of medication and interdisciplinary counseling for patients with GH and urinary tract disease are recommended.
Patient Summary: Drugs taken to reduce the risk of blood clotting can increase the risk of blood in the urine (called hematuria) and medical expenses for treatment. Drug-drug interactions are a relevant issue, especially in elderly patients and those with other medical conditions who are taking several drugs. Thoughtful discussion of individual risk profiles for hematuria and medication is therefore recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euf.2023.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of a light antithrombotic regimen after left atrial appendage occlusion: Insights from the LOGIC (left atrial appendage occlusion in patients with gastrointestinal or IntraCranial bleeding) international multicenter registry.
Cardiovasc Revasc Med
January 2025
Department of Cardiology, Ospedale dell'Angelo, AULSS3 Serenissima, Mestre, Venezia, Italy.
Background: Antithrombotic therapy (AT) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial fibrillation (NVAF) has the purpose of preventing device related thrombosis (DRT), avoiding embolic events; nevertheless, the correct antithrombotic regimen after LAAO is still under debate.
Aims: Aim of this substudy of the observational LOGIC registry was to describe the efficacy and safety of a light antithrombotic regimen, comprising single antiplatelet therapy or none, compared to a standard antithrombotic regimen, after a successful LAAO.
Methods: Patients with NVAF that underwent LAAO were previously included in the LOGIC registry.
Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study.
Cardiovasc Drugs Ther
January 2025
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, The Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangzhou, Guangdong Province, China.
Purpose: Coronary endarterectomy combined with coronary artery bypass grafting (CE-CABG) effectively achieves coronary revascularization in patients with diffuse atherosclerotic coronary artery disease (CAD). However, the loss of the subendothelial tissue at the CE-CABG coronary artery accelerates local thrombosis, leading to CE-CABG graft failure. Dual antiplatelet therapy (DAT) and warfarin plus aspirin (WPA) are the two most common anticoagulation strategies post CE-CABG.
View Article and Find Full Text PDFSwinging Pendulum Between Risks and Benefits of Antiplatelet Agents: A Call for Consistency in the Interpretation of Evidence and Guideline Recommendations.
Circulation
January 2025
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland (A.L., M.V.).
Screening for Deep Vein Thrombosis Using D-dimer Levels Based on Surgical Patients' Characteristics.
Cureus
December 2024
Surgical Gastroenterology, Kumamoto University, Kumamoto, JPN.
Purpose Owing to the shortage of surgeons and the decrease in medical staff in regional medical care, reducing unnecessary tests can limit the burden on the staff. In this study, we aimed to examine the predictors of deep vein thrombosis (DVT), such as D-dimer levels in patients who underwent surgery at our hospital, and determine the feasibility of screening in these patients. Knowledge of D-dimer levels can indicate the risk of DVT in patients about to undergo surgery.
View Article and Find Full Text PDFClinical Outcomes and Predictors of Poor Prognosis in Non-aneurysmal Subarachnoid Hemorrhage: A 10-Year Cohort Analysis.
Cureus
December 2024
Neurosurgery, Hospital de Braga, Braga, PRT.
Introduction A large majority of spontaneous subarachnoid hemorrhages (SAH) are attributed to aneurysm rupture, though the cause remains unknown in a notable percentage of cases. Non-aneurysmal SAH (naSAH) is generally thought to follow a more benign clinical course than aneurysmal SAH (aSAH); however, similar complications may occur, and poor outcomes are still possible. Given the limited research on naSAH, this study aims to characterize these patients and correlate clinical and radiographic findings with outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!